Consistency: Consistent. Review, PN annotation, and node mapping agree FBXL6 is an SCF substrate receptor. Deep research (falcon, UNVERIFIED) reports oncogenic substrates (phospho-p53, ETV6, CCNA2 degradative; HSP90AA1, KRAS, TKT non-degradative). These are not in the cache/PMID-verified, so the review correctly treats them as leads and does NOT add substrate-specific GO terms. No internal contradiction.
PN story / NEW pressure: PN asserts the generic adaptor MF. GOA has catalytic GO:0004842 (TAS, PMID:10531035) + generic proteolysis (TAS) + protein binding (SKP1) only — no validated substrate, no SCF-process IDA. Review MODIFY's GO:0004842→GO:1990756 (verified real) and MARK_AS_OVER_ANNOTATED on generic proteolysis. Note the falcon substrates also include K63 non-degradative ubiquitination, which GO:0031146 (proteasomal catabolism) does NOT cover — but since unverified, no new term is warranted. Conclusion: adaptor MF correctly captured; substrate functions remain inferred-only.
Mapping strategy: Gene does not change the node. FLAG (per batch pattern): F-box member with NO validated substrate in existing_annotations — adaptor MF is inferred from family/domain, not from a curated FBXL6 substrate. Group GO:1990756 still defensible on domain grounds (canonical F-box + SKP1 IPI). Scope/status correct.
Evidence alignment: PN cites only "15340381/rev"; review uses PMID:10531035, 33234069 (family reviews), SKP1 interactome PMIDs, and falcon leads. No PMID overlap with the PN placeholder; divergence benign.
Verdict: CONSISTENT / ACCEPT mapping (adaptor MF inferred-only). No YAML edits required. Substrate claims are appropriately held as unverified leads.